Breaking News, Collaborations & Alliances

UCB, Aitia Enter Strategic Drug Discovery Alliance in Huntington’s Disease

Will combine drug targets from Aitia's Gemini Digital Twins with UCB's expertise in drug research and preclinical model systems in neurodegeneration.

UCB, a global biopharmaceutical company, entered into an early drug discovery collaboration with Aitia, focused on the discovery and validation of novel drug targets and drug candidates for Huntington’s disease. The collaboration seeks to validate novel drug targets that are causally linked to clinical endpoints in Huntington’s disease. Aitia is involved in the application of Causal AI and “Digital Twins” to discover and develop new drugs. The collaboration will com...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters